deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04583969

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

A Multicenter Platform Trial of Putative Therapeutics for the Treatment of COVID-19 in Hospitalized Adults

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions COVID-19
Updated 20 times since 2020 Last updated: Jun 1, 2023 Started: Oct 23, 2020 Primary completion: Apr 22, 2022 Completion: Apr 22, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04583969, this PHASE2 trial focuses on COVID-19 and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 20 times since 2020, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Mar 2021 · 28 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2021 · 31 days · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Jul 2022 · 4 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Jul 2023 · 10 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2022 — Jul 2023 [monthly]

    Completed PHASE2

Show 15 earlier versions
  1. Jul 2022 — Sep 2022 [monthly]

    Completed PHASE2

    Status: Active Not RecruitingCompleted

  2. Mar 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: RecruitingActive Not Recruiting

  3. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  4. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  5. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE2

  6. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE2

  7. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE2

  8. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  9. May 2021 — Jun 2021 [monthly]

    Recruiting PHASE2

  10. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  11. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  12. Feb 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  13. Jan 2021 — Feb 2021 [monthly]

    Recruiting PHASE2

  14. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  15. Nov 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .